The estimated Net Worth of Pharmaceutical Co Ltdmillen... is at least $6.44 Million dollars as of 8 October 2019. Pharmaceutical Ltdmillen owns over 2,000,000 units of Ovid Therapeutics Inc stock worth over $6,440,000 and over the last 5 years Pharmaceutical sold OVID stock worth over $0.
Sign up
Pharmaceutical Ltdmillen OVID stock SEC Form 4 insiders trading
Pharmaceutical has made over 1 trades of the Ovid Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Pharmaceutical bought 2,000,000 units of OVID stock worth $5,000,000 on 8 October 2019.
The largest trade Pharmaceutical's ever made was buying 2,000,000 units of Ovid Therapeutics Inc stock on 8 October 2019 worth over $5,000,000. On average, Pharmaceutical trades about 2,000,000 units every 0 days since 2019. As of 8 October 2019 Pharmaceutical still owns at least 5,750,000 units of Ovid Therapeutics Inc stock.
You can see the complete history of Pharmaceutical Ltdmillen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharmaceutical Ltdmillen's mailing address?
Pharmaceutical's mailing address filed with the SEC is 1-1, NIHONBASHI-HONCHO 2-CHOME40 LANDSDOWNE STREET, , CHUO-KU, TOKYOCAMBRIDGE, M0MA, 103-866802139.
Insiders trading at Ovid Therapeutics Inc
Over the last 8 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan, and Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
What does Ovid Therapeutics Inc do?
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
What does Ovid Therapeutics Inc's logo look like?
Complete history of Pharmaceutical Ltdmillen stock trades at Ovid Therapeutics Inc
Ovid Therapeutics Inc executives and stock owners
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeremy Levin,
Chairman of the Board, Chief Executive Officer -
Amit Rakhit,
President, Chief Medical Officer -
Dirk Haasner,
Senior Vice President - Global Regulatory Affairs -
Timothy Daly,
Executive Vice President - Finance, Corporate Controller, Treasurer -
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
Pres, CEO & Chairman -
Thomas Michael Perone J.D., M.B.A.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jeffrey A. Rona,
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer -
Bart Friedman,
Lead Independent Director -
Douglas Williams,
Independent Director -
Karen Bernstein,
Independent Director -
Barbara Duncan,
Independent Director -
Jason Tardio,
Chief Commercial Officer -
Thomas Perone,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Luke Rosen,
Sr. VP of Accelerated Devel. & Community Engagement -
Dr. Claude Nicaise,
Head of R&D -
Dr. Dirk Haasner,
Sr. VP of Global Manufacturing & CMC QA -
Suzanne K. Wakamoto SHRM-SCP, SPHR,
Sr. VP of HR -
Lora Pike,
Sr. Director of Investor Relations & PR -
Jason Tardio M.B.A.,
Chief Commercial Officer & COO -
Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP,
Founder & Member of Scientific Advisory Board -
Matthew During,
Director -
Yaron Werber,
CBO, CFO, Sec. and Treas. -
Pharmaceutical Co Ltdmillen...,
-
Ana Ward,
SVP and General Counsel -
Robert Michael Poole,
Director -
Pharmaceutical Co Ltd Taked...,
-
Kevin Joseph Fitzgerald,
Director -
Margaret A. Alexander,
President and COO -
Jeffrey A Rona,
CBFO